MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

8 Ways the Medtech Industry is Responding to the Coronavirus

The 2019 n-cov has infected more than 60, 414 people worldwide and has a death toll of 1,370. Here are eight ways the industry is tackling the coronavirus.

  • To date there have been more than 31,000 cases of the 2019 n-COV (coronavirus) worldwide with a death toll of 630. There have been 12 confirmed cases in the U.S. The coronavirus was identified in the Chinese city of Wuhan on January 7. Since that time effects of the virus have been felt worldwide. From stocks falling on fears of the disease to shortages in surgical masks the impact of the coronavirus has been widespread.

     

    Image by Geralt on Pixabay
  • GenScript Launches Assay

    GenScript has launched an assay for the detection of the coronavirus. The Piscataway, NJ-based company said its test is a fast, one-step 2019-nCoV quantitative reverse-transcription polymerase chain reaction (qRT-PCR) detection assay, or reagent. GenScript's 2019-nCoV qRT-PCR detection assay is an enhancement on the World Health Organization's monoplex protocol published in January after the virus was identified in Wuhan city in the Hubei Province of China.

    GenScript said it had developed a multiplex protocol that can detect two to three genes in one reaction, therefore accelerating the detection time of all three genes associated with the virus. GenScript's production facility also has ISO13485 certification for oligo production to address the needs of the molecular diagnostic companies interested in developing kits for approval in the U.S. market.

    Image by Michal Jarmoluk on Pixabay
  • VivaLNK’s Sensors

    VivaLNK has developed a temperature sensor to combat the spread of coronavirus in China. The Campbell, CA-based company said the Shanghai Public Health Clinic Center (SPHCC) is using the sensor. SPHCC is designated as the primary treatment center in Shanghai, and confirmed patients from area hospitals are also sent to the SPHCC for quarantine and treatment.

    The VivaLNK temperature sensor has clearances from the CFDA, FDA, and CE, and is part of VivaLNK's medical wearable platform which includes sensors to monitor a variety of other vitals and biometrics.

    Image by CDC on Unsplash
  • Radiation Shield Technology Safety Suits

    Radiation Shield Technologies has developed the Demron Chemical Biological Radiological and Nuclear suits that enable healthcare workers to be externally monitored for the onset of fever, one of the first signs of the disease.

    The Miami, FL-based company said additionally, infected patients can also be monitored and externally cooled when infection transportation chambers are lined with the Demron fabric.

    Image by Gerd Altmann on Pixabay
  • Robots Lend a Helping Hand

    CloudMinds Technology, working in collaboration with China Mobile, has donated and sent 5G-enabled medical assistant Cloud Robots to offer assistance to Wuhan Tongji Tianyou Hospital, Wuhan Union Hospital, and Shanghai Sixth People’s Hospital. These are health institutions at the center of the outbreak. The Cloud Robots offer medical staff remote care options to measure patient temperature, clean and disinfect spaces, and deliver medicine, providing an effective solution for reducing the chances of infection for personnel and improving the level of isolation and control within quarantine environments.

    In a release, the company said in order to aid in the fight against the coronavirus, it is willing to open up its Cloud Robot Brain platform, and strategically cooperate with robotics companies to launch a variety of Medical Robots to the places of highest need.

     

    Geralt on Pixabay
  • Going Beyond Research Use Only

    Novacyt’s subsidiary Primerdesign recently launched a research use only (RUO) for the coronavirus, but plans call for it to seek approval. Paris, France-based Novacyt said it would launch a CE-Mark approved nCoV test in on Feb. 17.

    The company also applied for Emergency Use Approval (EUA) of the test from FDA.  EUA approval would allow laboratories in the US to use the nCoV test for clinical diagnosis on a temporary basis.

    Image by Geralt on Pixabay
  • Johnson & Johnson’s Strategy

    Johnson & Johnson joined the fray by mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the outbreak. As part of this work, the company has initiated efforts to develop a vaccine candidate against 2019-nCoV and broadly collaborate with others to screen a library of antiviral therapies. The New Brunswick, NJ-based company said by identifying compounds with antiviral activity against 2019-nCoV may contribute to providing immediate relief to the current outbreak.

    J&J stands out from all of the other companies in the space because it is one of the few major strategics that has a presence in both medtech and pharma. J&J can truly touch all corners when it comes to the fight against the coronavirus.

    Image by Peggy Marco on Pixabay
  • Co-Diagnostics Emerges

    Co-Diagnostics has been in the news lately for its efforts in detecting the coronavirus. The Salt Lake City-based company just launched its research use only (RUO) CoPrimer test for the coronavirus. Co-Diagnostics said the test is ready for sale to appropriate laboratories, hospitals, and institutions in need of a solution to the current coronavirus epidemic.

    The announcement follows two weeks of efficient design, development, and verification activities to ensure that the polymerase chain reaction (PCR) test’s performance, first announced on January 23, meets the requirements of a large and growing market for coronavirus detection. The test was designed using the Company’s proprietary process, including the CoDx Design software system, to rapidly identify and verify the most optimal target on the 2019-nCoV genome for a PCR assay.

    The company has been shining the spotlight on the disease and its CEO Dwight Egan was featured on CNBC Squawk Box Asia.

    Image by mcmurryjulie on Pixabay
  • FDA’s Plan

    Technically FDA isn’t the medtech industry. It just regulates it. But the federal agency’s response (s) to the coronavirus should definitely go at the top of this list. FDA fired away with a strategy that would see it working with interagency partners product developers, international partners, and global regulators to expedite the development and availability of medical products needed to diagnose, treat, mitigate, and prevent outbreaks.

    And just a few days later FDA took action on this plan by issuing an emergency use authorization (EUA) for the Centers for Disease Control and Prevention’s Coronavirus detection test. Up until now, the 2019-nCoV Real-Time RT-PCR Diagnostic Panel had only been used at CDC laboratories.

    With this rapid response, it will be interesting to see the other strategies that FDA puts in place to tackle the coronavirus.

500 characters remaining